SM-05-947

SM-05-947 is a novel, selective small molecule inhibitor of histone deacetylase 6 (HDAC6) developed for cancer immunotherapy. It functions as an epigenetic modulator that reprograms the tumor microenvironment by shifting tumor-associated macrophages (TAMs) from a pro-tumoral M2-like phenotype to an anti-tumoral M1-like phenotype. This phenotypic switch enhances macrophage-mediated anti-tumor activities, including increased phagocytosis of tumor cells and improved antigen cross-presentation via MHC class I. Preclinical studies in immunocompetent murine melanoma models have shown that SM-05-947 significantly reduces tumor growth both as a monotherapy and in combination with anti-PD1 antibodies, demonstrating superior potency and selectivity compared to earlier generations of HDAC6 inhibitors.